Navigation Links
PersonalLAB™ Junior

ProductsPersonalLAB™ Junior
Company Sierra Resources International, Inc.
Item PersonalLAB™ Junior
Features 
  • Full automation, just load and leave.
  • Open system capable of running many manufacturers' microplate assays.
  • Stores over 500 assay protocols on the system.
  • Stores kit and reagent lot information.
  • Primary tube sampling and bar code reading.
  • Patented level sensing with sample clot detection.
  • Runs multiple microplate assays simultaneously.
  • Programmable sample dilution capability.
  • Sample processing using disposable conductive plastic tips.
  • Closed incubation system. Microplate is protected from evaporation and light.
  • Calculates both quantitative and qualitative results.
  • Customizes result data and printouts.
  • Remote diagnostic trouble-shooting via internal modem.
  • ASIM Bi-directional Interface capability (optional).
Description The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and specifications.
Info Sierra Resources International, Inc.
Customer Service: 505-983-2027
Web site: http://www.sierraresources.com/index.html

Related medicine products :

1. Miditron Junior II
2. Shandon Grosslab Junior Grossing Workstation
3. IntelliVue MP20 Junior
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products:
(Date:12/17/2009)... feature is by Devon Herrick, PhD, Senior Fellow at ... often assume they have little control over how much ... cannot be scheduled, doctors prescribe treatments and employers provide ... However, there are many overlooked ways to trim your ... ,, Cut your prescription costs: ...
(Date:12/17/2009)... The National Council on Disability ... JW Marriott Houston, 5150 Westheimer, Houston, TX, beginning at ... at 11:00 a.m. on Thursday, January 21, 2010. This ... believes it is vital to hear from communities around ... for people with disabilities. This meeting will provide another ...
(Date:12/17/2009)... MA Brandeis University selected Jay and Maureen Neitz, the ... use of gene therapy to treat vision disorders, as ... in Vision Sciences. , The award is funded by ... gift from Brandeis graduates Jay Pepose ,75 and Susan ... graduate research fellowships in vision science. , The Neitzes, ...
(Date:12/17/2009)... the particle might someday ease accompanying lung infections , , ... severe pneumonia when infected with the swine flu virus, ... why. , A key to the severity of the ... (TH17), which helps the immune system fight off germs ... in swine-flu patients at 10 Spanish hospitals last summer ...
(Date:12/17/2009)... Studies Important ,for the R&D Informatics Industry, , ... ... Cambridge Healthtech Institute is pleased to announce the participation of ... R&D Informatics Systems conference to be held on February 3-5, ... CA. This meeting has been integrated in the Informatics Channel ...
Breaking Medicine News(10 mins):Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3
... to provide additional modality integrationsINDIANAPOLIS, March 9 ... pleased to announce the worldwide release of its ... Key features of this release include integrated ECG ... Hemodynamic system. Synapse ProSolv cardiovascular 4.0.1 will ...
... Improvement Plus to Provide Information on Medicare Advantage ... Farmers MarketCOLUMBIA, S.C., March 9 A series ... Medicare beneficiaries with chronic illness maintain a healthy ... Plans designed for their unique needs will be ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... the latest findings in laboratory, translational and clinical cancer ... therapeutic approaches, as well as strides being made in ... the best advantage of the meeting,s scientific abstracts and ... will be available online at www.aacr.org on Friday, March ...
... Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., March ... IDMI ) today announced that the European Commission ... (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, ... that typically affects children and young adults. The ...
... author reviews the consequencesROCHESTER, Minn., March 9 ... the treating physician recommends discharge, the consequences may ... the need for readmission, according to a review ... Proceedings. Additionally, the article examines the effect of ...
Other Medicine News:Health News:ProSolv Releases New Cardiovascular Software 2Health News:ProSolv Releases New Cardiovascular Software 3Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3
(Date:12/17/2009)... SAN DIEGO, Dec. 17 Suneva Medical, ... that it has signed a multi-million dollar line ... The line of credit facility will be ... only FDA-approved microsphere-enhanced collagen dermal filler on the ... Aesthetic Market growth objectives. ,, "Today Suneva Medical ...
(Date:12/17/2009)... SAN DIEGO, Dec. 17 SpectraScience, Inc., (OTC ... CEO, Jim Hitchin has issued the following letter to ... we are pleased to announce that through the recent ... we are undertaking several initiatives critical to ramping our ... making key additions to our European sales force. We ...
(Date:12/17/2009)... WALTHAM, Mass., Dec. 17 Decision Resources, ... firms focusing on pharmaceutical and healthcare issues, finds ... indicate there is a high need for diabetes ... percent who say there is a high need ... patients favor agents with excellent glucose lowering ability ...
Breaking Medicine Technology:Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 3SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3EPA fellow studies effect of mercury in toads 10419 1EPA fellow studies effect of mercury in toads 10419 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 3OriGene Technologies Acquires Marligen Biosciences 14527 1OriGene Technologies Acquires Marligen Biosciences 14527 2